NOTICE OF INTENT TO SOLE SOURCE - Psomagen, Inc. GEM-X Cell QC, sequencing and data analysis

Closed Special Notice Posted

Solicitation number
PCA-NCI-09798
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
Rockville, Maryland 20850, United States

Notice details come from SAM.gov. Updated .

About this opportunity

The National Cancer Institute issued a Notice of Intent to Sole Source with Psomagen, Inc. on September 15, 2026, with a response deadline of September 21, 2026, for quality control, sequencing library generation using 10X Chromium GEM-X Single Cell 5p RNA technology, and expression analysis services on frozen clinical xenograft biosamples supporting ongoing research studies. This procurement is not an open competition; NCI intends to negotiate directly with Psomagen based on the company's proprietary ownership and development of the required testing services and existing integration with NCI's research data infrastructure. The biosamples present a critical constraint: they remain viable for no more than two hours during transport, making consistency with prior data from Psomagen's existing work operationally essential. Interested vendors may submit a capabilities statement and past performance documentation addressing their ability to meet the full requirement and integrate with existing Psomagen quality control, sequencing, and data analysis processes. Submissions must reference identifier "PCA-NCI-09798" and reach the point of contact by the closing date. The Government retains sole discretion to determine whether to conduct the procurement on a competitive basis based on vendor responses. An award notice filed September 22, 2026 documents that NCI issued Purchase Order 75N98026P01661 to Psomagen, Inc. for $24,582.50 under FAR 5.301(c) sole-source authority.

Notice text

Title:  Psomagen, Inc. GEM-X Cell testing (ongoing studies)

This is a Notice of Intent to Sole Source (NOI), not a request for proposal. The National Cancer Institute intends to negotiate on an other-than-full-and-open competition basis with Psomagen, Inc., 1330 Piccard Dr., Suite 103, Rockville, MD  20850-4372 for quality control of submitted single cell samples, generation of sequencing libraries with 10X Chromium GEM-X Single Cell 5p RNA, and expression analysis data of (frozen) clinical xenograft biosamples.  The testing is being obtained from Psomagen, Inc.  to remain consistent with prior data of ongoing research studies.  A critical factor in filling the requirement is the limited viability (no more than 2 hours transport time) of the irreplaceable study biosamples. 

While this pre-solicitation does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy this requirement. The Government understands that Psomagen, Inc. is the owner and developer of the required proprietary testing services currently used by NCI in its ongoing research studies.  However, vendors who believe that they can provide the capability required to fully meet the Government's requirement may submit a capabilities statement, including past performance, in writing to the identified point of contact prior to the closing date and time of this notice. Interested parties should clearly address the challenge of integrating with existing Psomagen quality control, sequencing libraries and expression analysis data.  Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Interested parties may identify their interest and capability to respond to the requirement by referencing “PCA-NCI-09798.”

The statutory authority for this sole source requirement is 41 U.S.C. 3204(b)(2) as implemented by FAR Overhaul 12.102(a) only one source is available. THIS IS NOT A REQUEST FOR PROPOSAL.

All responsible sources that could provide comparable products may submit a capability statement via email to Christine Biser at:

ChristineBi@mail.nih.gov by 12:00 pm EASTERN Daylight Time, Wednesday, September 24, 2026.

Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Christine Biser at ChristineBi@mail.nih.gov.

Files

File Type Posted
H.7 Award Notice.docx DOCX document

Similar open opportunities

Opportunity Agency Set-aside Responses due
RNA sequencing and whole genome sequencing services Bethesda, Maryland 20892, United States · NAICS 32599 Office of Logisitics and Acquisition Operations No set-aside
Notice of Intent to Sole Source – AB Sciex LLC Maryland 20892, United States · NAICS 339112 NIH Clinical Center No set-aside
NOI - DNA Sequencing of Bone Marrow Failure Syndro NAICS 325413 Office of Logisitics and Acquisition Operations No set-aside
1-Year OEM Service Contract - (2) Revvity Celigo S Imaging Instruments (VRC) Bethesda, Maryland 20892, United States · NAICS 811210 National Institute of Allergy and Infectious Diseases No set-aside
Maintenance Agreement: AxioScan. Z1 Microscopes Maryland 20892, United States · NAICS 811210 National Institute of Child Health and Human Development No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors